arrow
R

Robert C. Read

GlaxoSmithKline
H指数:70
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence - a meeting report

疫苗效力和许可的III期临床试验替代方案:真实世界证据的作用——会议报告

2026-08-010
OAAI
BPZE1 vaccination induces IL-17+ and IL-22+ CD4+ T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation

BPZE1疫苗接种诱导产生与人类鼻粘膜分泌性IgA反应相关的IL-17+和IL-22+ CD4+ T细胞:对致病性百日咳博德特菌定植的影响

2026-04-180
OAAI
Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection study

安全性、定植动力学、传染性和保护性免疫相关性在接种了Bordetella pertussis的英国健康成年人中的研究:一项单中心、开放标签、1期、受控人体感染研究

2026-03-230
OAAI
Reactogenicity and Immunogenicity following Heterologous and Homologous Third Dose COVID-19 vaccination in UK Adolescents (Com-COV3): A Randomised Controlled Non-Inferiority Trial

同源和异源第三剂COVID-19疫苗接种后英国青少年的反应原性和免疫原性(Com-COV3):一项随机对照非劣效性试验

2025-12-010
OAAI
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

蛋白为基础的初次免疫(NVX-CoV2373)与mRNA加强免疫(BNT162b2)的异源COVID-19疫苗接种方案可诱导强烈的体液免疫反应:COV-BOOST试验结果

2025-08-070
OAAI
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development

门诊实验性感染的风险分析作为一种开发可负担RSV疫苗的途径

2025-04-150
OA
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

青少年 (Com-COV3) 异源或分段第二次剂量新型冠状病毒肺炎疫苗接种后的反应原性、免疫原性和突破性感染: 一项随机对照试验

2023-09-015
OAAI
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

英国异源和同源第三新型冠状病毒肺炎疫苗给药方案后免疫反应的持久性: cov-boost试验的八个月分析

2023-07-0115
OAAI
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study-A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

Com-COV2研究中异源COVID疫苗接种计划中免疫反应的持久性-一项纳入mRNA,病毒载体和蛋白质佐剂疫苗的单盲,随机试验

2023-06-017
OAAI
Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT

在初级保健中出现的儿童下呼吸道感染的抗生素: ARTIC-PC RCT

2023-06-011
OA
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

接种间隔对同源与异源新型冠状病毒肺炎疫苗接种程序的反应原性、免疫应答峰值及衰减的影响:Com-COV随机对照试验的探索性分析

2022-11-0126
OAAI